


PRODUCT INFORMATION



Seralutinib

Item No. 37754

CAS Registry No.: 1619931-27-9
Formal Name: N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)-2-pyrazinyl]amino]ethyl]phenyl]-5-methyl-3-pyridinecarboxamide
Synonyms: GB002, PK 10571
MF: C₂₇H₂₇N₅O₃
FW: 469.5
Purity: ≥98%
UV/Vis.: λ_{max}: 273 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Seralutinib is supplied as a solid. A stock solution may be made by dissolving the seralutinib in the solvent of choice, which should be purged with an inert gas. Seralutinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of seralutinib in DMSO is approximately 25 mg/ml and approximately 10 mg/ml in ethanol and DMF.

Description

Seralutinib is an inhibitor of PDGFR, c-Kit, and colony stimulating factor 1 receptor (CSF1R).¹ It inhibits PDGF-BB-induced phosphorylation of ERK in PDGFR α -dependent H1703 human lung epithelial cells, human pulmonary arterial smooth muscle cells (HPASMCs), which express PDGFR α and PDGFR β , and human lung fibroblasts (HLFs), which express higher levels of PDGFR β than PDGFR α (IC₅₀s = 74, 49, and 62 nM, respectively). Seralutinib also inhibits stem cell factor-induced c-Kit autophosphorylation in human pulmonary endothelial cells (HPAECs) and M-CSF-induced CSF1R phosphorylation in human primary differentiated macrophages (IC₅₀s = 7.8 and 14.4 nM, respectively). It inhibits the proliferation of H1703 cells and PDGF-BB-induced HPASMCs and HLFs (IC₅₀s = 32, 33, and 29 nM, respectively). Seralutinib (2.5 mg/kg) prevents increases in pulmonary artery systolic pressure in a rat model of pulmonary arterial hypertension induced by monocrotaline (Item No. 16666) pneumonectomy when administered *via* passive inhalation.

Reference

1. Galkin, A., Sitapara, R., Clemons, B., *et al.* Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. *Eur. Respir. J.* **60**(6), 2102356 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/15/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM